AOD-9604 research in Canada investigates the fat-loss signalling properties of this synthetic fragment of human growth hormone. AOD-9604 (Advanced Obesity Drug 9604) is a stabilized 16-amino acid peptide corresponding to the C-terminal lipolytic domain of HGH (amino acids 176-191). Unlike full-length HGH, AOD-9604 does not activate the GH receptor and does not produce IGF-1 increases or insulin resistance. Canadian metabolic and adipose biology researchers study AOD-9604 for its selective effects on fat cell lipolysis without the broader anabolic and diabetogenic effects of full HGH.
Lipolysis Mechanism Research
HGH exerts its lipolytic effects through a specific domain in its C-terminus rather than through the GH receptor. AOD-9604 is believed to activate beta-3 adrenergic receptors on fat cells rather than the GH receptor, stimulating cAMP production and PKA-mediated phosphorylation of hormone-sensitive lipase (HSL). Canadian adipose biology researchers study this beta-3 AR mechanism to understand how HGH-derived peptide fragments can activate lipolysis through a GH receptor-independent pathway.
Adipocyte Biology Research
Canadian researchers use AOD-9604 to study lipid metabolism regulation in white adipose tissue (WAT) and brown adipose tissue (BAT). Research investigates whether AOD-9604 preferentially activates lipolysis in visceral versus subcutaneous adipocytes, and whether it influences adipokine secretion (adiponectin, leptin) in cell culture models.
Sourcing AOD-9604 in Canada
Research-grade AOD-9604 is available from EhBuddy Peptides in Canada. Lab-tested for purity. For laboratory research use only.
AOD-9604 offers Canadian fat biology researchers a selective HGH-derived lipolytic tool that separates adipose tissue effects from the broader growth-promoting pharmacology of full-length growth hormone.
